文献速递慢阻肺

慢阻肺嗜酸性炎症:从炎症标志物到可治疗特质

Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait.
PubMed 文献 · Thorax · 2020-10-29

本文综述了血嗜酸性粒细胞计数作为慢阻肺(COPD)生物标志物的作用,基于两次国际专家会议共识并结合文献,探讨其与吸入糖皮质激素(ICS)反应性的关联及作为可治疗特质的潜力。现有证据提示血嗜酸性粒细胞可能预测ICS减少急性加重的获益,但预测阈值不一,机制未明,临床应用仍存争议。

要点

  • 血嗜酸性粒细胞计数可用于评估COPD患者对ICS的反应性,辅助分层治疗。
  • 预测ICS获益的嗜酸性粒细胞水平通常为100-300细胞/µL或更高,处于传统正常范围。
  • 嗜酸性表型可能是可治疗特质,但统一共识和实用检测方法仍待建立。

核心结论

  • 部分证据支持血嗜酸性粒细胞作为COPD可治疗特质的潜在生物标志物,但证据仍不充分,研究正在进行中。

主要发现

  • 多项研究和两项荟萃分析提示外周血嗜酸性粒细胞可能与COPD患者ICS减少急性加重的获益呈正相关。
  • 研究设计、持续时间及预测ICS反应的嗜酸性粒细胞水平定义存在差异。
  • 通常在嗜酸性粒细胞水平为100-300细胞/µL(或更高)时可见反应,该水平传统上被视为正常范围。
  • 针对白细胞介素-5的靶向治疗取得一定成功,提示嗜酸性表型可能是可治疗特质。

关键数值与推荐

  • 血嗜酸性粒细胞预测ICS反应的阈值通常为100-300细胞/µL(或更高)。

临床怎么用

  • 可考虑使用血嗜酸性粒细胞计数辅助评估COPD患者对ICS的反应性,以指导治疗分层。
  • 需注意嗜酸性粒细胞预测ICS获益的证据仍不充分,临床应用应结合个体情况。

局限性

  • 嗜酸性粒细胞水平与ICS效应关联的机制尚不明确。
  • 现有研究设计、持续时间及预测阈值不一,缺乏统一标准。
  • 缺乏统一的共识和实用、可及、可负担的生物标志物应用方法。
  • 生物标志物驱动治疗的明确合理依据、ICS撤药的初级与二级医疗衔接指南以及财务激励不足等挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The heterogeneity of chronic obstructive pulmonary disease (COPD) creates many diagnostic, prognostic, treatment and management challenges, as the pathogenesis of COPD is highly complex and the underlying cellular and molecular mechanisms remain poorly understood. A reliable, easy-to-measure, clinically relevant biomarker would be invaluable for improving outcomes for patients. International and national guidance for COPD suggests using blood eosinophil counts as a biomarker to help estimate likely responsiveness to inhaled corticosteroids (ICS) and, potentially, to aid effective management strategies. However, with the mechanism underlying the association between higher eosinophil levels and ICS effect unknown, use of the blood eosinophil count in COPD continues to be widely debated by the respiratory community.Two international meetings involving respiratory medicine specialists, immunologists and primary and secondary care clinicians were held in November 2018 and March 2019, facilitated and funded by GlaxoSmithKline plc. The aims of these meetings were to explore the role of eosinophils in the disease processes of COPD and as prognostic and diagnostic markers, and to identify areas of deficient knowledge that warrant further research. The consensus views of the attendees on key topics, contextualised with current literature, are summarised in this review article, with the aim of aiding ongoing research into the disease processes of COPD and the development of biomarkers to aid clinical management.Under certain conditions, eosinophils can be recruited to the lung, and increasing evidence supports a role for eosinophilic inflammation in some patients with COPD. Infiltration of eosinophils across the bronchial vascular epithelium into the airways is promoted by the actions of immunoregulatory cells, cytokines and chemokines, where eosinophil-mediated inflammation is driven by the release of proinflammatory mediators.Multiple studies and two meta-analyses suggest peripheral blood eosinophils may correlate positively with an increased likelihood of exacerbation reduction benefits of ICS in COPD. The studies, however, vary in design and duration and by which eosinophil levels are viewed as predictive of an ICS response. Generally, the response was seen when eosinophil levels were 100-300 cells/µL (or higher), levels which are traditionally viewed within the normal range. Some success with interleukin-5-targeted therapy suggests that the eosinophilic phenotype may be a treatable trait.The use of biomarkers could help to stratify treatment for COPD-the goal of which is to improve patient outcomes. Some evidence supports eosinophils as a potential biomarker of a treatable trait in COPD, though it is still lacking and research is ongoing. A unified consensus and a practical, accessible and affordable method of utilising any biomarker for COPD was thought to be of most importance. Challenges around its utilisation may include presenting a clear and pragmatic rationale for biomarker-driven therapy, guidance on ICS withdrawal between primary and secondary care and a lack of financial incentives supporting broad application in clinical practice. Future treatments should, perhaps, be more targeted rather than assuming the primary disease label (COPD or asthma) will define treatment response.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2020. PMID: 33122447. doi:10.1136/thoraxjnl-2020-215167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。